7 November 2022 - The UK’s MHRA has updated its 2021 guidance on biosimilars to allow interchangeability between biosimilars if they use the same reference medicinal product.
On 6 November, the British regulatory agency updated a 2021 document titled Guidance on the licensing of biosimilar products. It has expanded the interchangeability section of the document to account for biosimilars that have the same reference product.